[Adjuvant treatment of head and neck cancers: advances and challenges].
Following the release, in 2004, of the results from 2 multicentric, phase III studies, the adjuvant treatment of locally advanced head-and-neck cancers nowadays belongs to Level I of Evidence-Based Medicine, with the advent of concomitant, high-dose chemoradiation. The concurrent delivery of radiotherapy (60 to 66 Gy using a conventional fractionation) and high-dose, bolus cisplatin (100 mg/m2, days 1, 22 and 43) is considered, in post-operative setting, as the standard approach in patients with locally advanced disease. Future adjuvant treatments should anchor to the development of high-precision irradiation techniques, as well as concomitant delivery of radiotherapy with more efficacious cytotoxic drugs and/or targeted therapies.
Bernier
Jacques
J
Service de radio-oncologie, Clinique de Genolier, 1272 Genolier, Suisse. jbernier@genolier.net
D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data; D003131:Combined Modality Therapy; D019468:Disease Management; D019317:Evidence-Based Medicine; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D018714:Radiotherapy, Adjuvant / Q000379:methods / Q000706:statistics & numerical data; D016896:Treatment Outcome
D000970:Antineoplastic Agents